‘Hard Truths’ For Sentinel: US FDA Scales Back Active Surveillance Ambitions

 
• By Grace Moser
  
The FDA is limiting Sentinel development due to budget constraints. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Post-Marketing Regulation & Studies

More from R&D